Samuel Ofori, MD
Medical Oncology · Valdosta, GANPI 1548285703
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.5%), other and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Novartis at 56.5% of the total. 2025 is the largest year on record at $1,512, more than ten times the $140 reported in 2019. That places this record below the midpoint for medical oncology clinicians in GA, where the typical reported total is $5,509.
Across 124 payments — averaging $31.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Gilead$189
- Merck$152
- Amgen$152
- Exelixis Inc.$140
- E.r. Squibb & Sons, L.L.C.$133
- plus $923 from 22 others
Across 3 payments — averaging $1121.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3K
What the payments were for
- Food & beverage$1,88448%
- Education$1404%
- Other$1,86348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 41 | $2,198 |
| Gilead(2 entities) | 10 | $189 |
| Merck | 4 | $152 |
| Amgen | 10 | $152 |
| Exelixis Inc. | 4 | $140 |
| E.r. Squibb & Sons, L.L.C. | 7 | $133 |
| Pfizer | 6 | $111 |
| Astellas Pharma US Inc | 5 | $96 |
| Bristol Myers Squibb | 4 | $86 |
| AbbVie | 4 | $84 |
| Daiichi Sankyo Inc. | 4 | $79 |
| Johnson & Johnson | 4 | $73 |
| Genentech USA, Inc. | 3 | $51 |
| Ipsen Biopharmaceuticals, Inc | 2 | $45 |
| Tempus AI, Inc | 2 | $39 |
| AstraZeneca(2 entities) | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Sobi, Inc | 1 | $21 |
| Bayer | 1 | $20 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Array Biopharma Inc | 1 | $14 |
| EMD Serono, Inc. | 1 | $13 |
| Dova Pharmaceuticals | 1 | $13 |
| GSK | 1 | $13 |
How this compares
$3,888 in reported general payments places this provider in the 40th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 48 | $793,251 |
| PomalystPomalidomide | 35 | $790,334 |
| RevlimidLenalidomide | 37 | $687,546 |
| CabometyxCabozantinib S-Malate | 17 | $520,731 |
| XtandiEnzalutamide | 31 | $438,836 |
| Lenalidomide | 29 | $406,914 |
| VerzenioAbemaciclib | 18 | $321,930 |
| IbrancePalbociclib | 17 | $258,011 |
| VenclextaVenetoclax | 13 | $91,252 |
| EliquisApixaban | 85 | $50,163 |
| Imatinib Mesylate | 17 | $27,903 |
| XareltoRivaroxaban | 21 | $13,050 |
| Deferasirox | 14 | $3,727 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 135 | $3,387 |
| Letrozole | 164 | $2,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $20 | $793,25148 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $133 | $790,33435 claims |
| Bristol Myers SquibbRevlimid | $86 | $687,54637 claims |
| Exelixis Inc.Cabometyx | $140 | $520,73117 claims |
| Astellas Pharma US IncXtandi | $96 | $438,83631 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $20 | $322,06831 claims |
| PfizerIbrance, Eliquis | $111 | $308,175102 claims |
| AbbVieVenclexta | $84 | $91,25213 claims |
| Johnson & JohnsonXarelto | $73 | $13,05021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Valdosta
- Swapna Narayana Rao GariValdosta$2K
- Samir KhleifAugusta$337K
- Nabil SabaAtlanta$225K
- Sreekanth ReddyVidalia$116K
- Hagop YoussoufianDecatur$78K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.